First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
- Authors: Babicheva L.G.1, Poddubnaya I.V.1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 22, No 2 (2020)
- Pages: 119-125
- Section: Original Article
- URL: https://journals.rcsi.science/1815-1434/article/view/34967
- DOI: https://doi.org/10.26442/18151434.2020.2.200125
- ID: 34967
Cite item
Full Text
Abstract
The aim is to evaluate the efficacy of the first-line rituximab-containing therapy of B-cell lymphoproliferative diseases in Russian clinical practice between 2014 and 2017.
Materials and methods. In the post-authorisation multicenter study EQUILIBRIUM were included 1 thousand patients aged from 21 to 91 with B-cell non-Hodgkin’s lymphoma or chronic lymphatic leukemia who had received at least 4 cycles of rituximab-containing therapy using the drug Acellbia®. This article was devoted to the group of indolent non-Hodgkin’s lymphomas and included 253 patients: follicular lymphoma – 51% of cases, marginal zone lymphoma – 44% of patients, extremely rare were registered lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia – in 3% and in 2% of cases, respectively. The median age in patients with indolent non-Hodgkin’s lymphomas was 62 years (21–91 years). The vast majority of patients were diagnosed with stage III–IV – 190 (75%) of patients. More than 1/2 (53.4%) of patients in routine practice received R-CHOP therapy as a first-line. BR regimen was applied in 15.4% of cases, 14.2% of patients were treated with R-CVP/R-COP. We indicated rare use of rituximab as monotherapy in induction mode – only 4.4% of patients. And 2.4% of patients were treated with fludarabine-containing therapy.
Results. The final assessment of the effect was carried out after 6–8 cycles of treatment and as a result the overall effect was more than 90%: the frequency of complete remission was 61%, partial responses – 32.9%. The progression admitted only in 17 (6.7%) patients among 253 observed. With a median of 15 months, the median of overall survival and event-free survival was not achieved.
Conclusion. The use of the available and appropriate treatment according to the domestic clinical guidelines with the inclusion of the Russian biosimilar anti-CD20 monoclonal antibody – Acellbia®, demonstrates high direct efficacy and satisfactory long-term treatment results comparable to the retrospective analysis of the previous clinical studies of the original drug rituximab.
Full Text
##article.viewOnOriginalSite##About the authors
Lali G. Babicheva
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0001-8290-5564
Cand. Sci. (Med.)
Russian Federation, MoscowIrina V. Poddubnaya
Russian Medical Academy of Continuous Professional Education
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowReferences
- Garrison LP, Neumann PJ, Erickson P et al. Using Real World Data for Coverage and Payment Decisions: the ISPOR Real World Data Task Force Report. Value Heal 2007; 10 (5): 326–35.
- Поддубная И.В., Бабичева Л.Г. Роль бендамустина в лечении В-клеточных неходжкинских лимфом. Современная онкология. 2018; 20 (4): 41–8. [Poddubnaya I.V., Babicheva L.G. The role of bendamustine in the treatment of B-cell non-Hodgkin lymphomas. Journal of Modern Oncology. 2018; 20 (4): 41–8 (in Russian).]
- Poddubnaya IV, Babicheva LG et al. Comparison of farmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma. J Clin Oncology 2014; 32. ASCO Annual Meeting Proceedings. Аbs e19545